Skin Cancers - Opportunity Assessments, Epidemiology Studies, Market Dynamics, and Pipeline Analytics H2 2020
|出版商||GervanoRA Data Services LLP||商品编码||968652|
|出版日期||内容资讯||英文 343 Pages
|皮肤癌:机会评估，流行病学研究，市场动态，及开发平台分析(2020年下半年) Skin Cancers - Opportunity Assessments, Epidemiology Studies, Market Dynamics, and Pipeline Analytics H2 2020|
|出版日期: 2020年11月03日||内容资讯: 英文 343 Pages||
GervanoRA's pipeline analysis and opportunity assessment report "Skin Cancers - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H2 2020" analyzed and assessed Skin Cancer pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Skin Cancers drugs industry.
The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Skin Cancers area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Skin Cancers drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.
Our comprehensive analysis on the Skin Cancers drug pipeline identified 681 drug candidates undergoing different stages of development- from Early R&D stage to Phase 3 stage and Pre-Registration. Among these, a total of 388 drug candidates are in clinical stages of development and 195 molecules are in non-clinical stage of development. The drug pipeline consists of three (03) pipeline molecules in pre-registration, 36 pipeline molecules are in late clinical stage of development (Phase 3), and a total of 163 pipeline molecules in early clinical stage of development (Phase 1). The report also aims to provide analytics and deep insights on the expected market share of the key Phase 3 and Phase 2 pipeline drugs for a better understanding of the Skin Cancers market in the coming years and know the competition which is paramount for any new entrant.
The report has covered more than 575 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.
12.1: EMERGING COMPANIES